Stock Market Movers: Best and Worst Performers of 14 October 2026

U.S. inflation rose 0.6% in September, bringing the annual rate to 3.7%. Shoppers are adapting to higher prices by using discounts and store brands. Kroger announced plans to cut 3,000 corporate jobs over three years, but the impact on stores and prices is unclear. The company is also offering fuel rewards promotions.

Bristol Myers Squibb reported positive topline results from a Phase 3 trial for its investigational IPF treatment, highlighting progress in addressing the disease.

Bristol Myers Squibb's iberdomide (Zenbexus) with daratumumab and dexamethasone (ZDd) showed a 51% reduction in disease progression risk vs standard treatment in a phase 3 trial. Median PFS was 42 months with ZDd vs 20 months with DVd. The FDA approved ZDd for RRMM in August 2026 based on earlier MRD-negative CR results. Full trial results will be presented in 2026.

Vir Biotechnology (VIR) and Gilead Sciences (GILD) have partnered to develop cancer immunotherapies. Vir will receive up to $135M upfront, including $65M cash and a $25M equity investment, with potential future payments of $1.74B. Vir's PRO-XTEN technology aims to reduce side effects and improve targeting. VIR is down 0.75%, GILD up 2.18%.

Vir Biotechnology and Gilead Sciences agreed to collaborate on cancer therapies for solid tumors, with a deal potentially worth up to $1.88 billion. Vir will receive $90 million upfront and could earn additional milestone payments and royalties. The partnership focuses on developing three drug candidates using Vir's technologies. Vir shares rose over 10% in premarket trading.

Vir Biotechnology (VIR) shares rose 10% premarket after a licensing deal with Gilead (GILD) for cancer drug development, potentially worth $1.9B. The agreement involves Vir's PRO-XTEN technology.